Originally posted by the Voice of America.
Voice of America content is produced by the Voice of America,
a United States federal government-sponsored entity, and is in
the public domain.


Johnson & Johnson One-dose Vaccine 66% Successful

VOA News

   U.S. pharmaceutical and medical device maker Johnson & Johnson says
   after a global trial, the COVID-19 vaccine it has developed is 66%
   effective in preventing infection.

   The one-dose vaccine, which was developed by the company's Belgian
   subsidiary Janssen, appears to be 85% effective in preventing serious
   illness, even against the South African variant.

   Of the 44,000 people who participated in the trail in the U.S., South
   Africa and Brazil, no one who was given the vaccine died, the company
   said.

   "The potential to significantly reduce the burden of severe disease, by
   providing an effective and well-tolerated vaccine with just one
   immunization, is a critical component of the global public health
   response," Paul Stoffels, chief scientific officer of Johnson &
   Johnson, said in a company press release.

   "A one-shot vaccine is considered by the World Health Organization to
   be the best option in pandemic settings, enhancing access, distribution
   and compliance," said the statement.

.